Pharma Bio Services (PBSV) AI Stock Analysis

• Market Cap: $9.87M
• Dividend Yield: N/A
• Average Volume (3M): 2.99K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.22
• Revenue Growth: -36.50%
• EPS Growth: -181.27%
• Country: US
• Employees: 75
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.02
• Shares Outstanding: 22,929,743
• 10 Day Avg. Volume: 5,292
• 30 Day Avg. Volume: 2,994
• PEG Ratio: N/A
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.09
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Pharma Bio Services is experiencing significant financial challenges with declining revenue and weak cash flows despite a strong balance sheet. The technical indicators suggest a bearish trend, and the valuation is unattractive with a negative P/E ratio. The overall outlook remains cautious, with a need for improvement in financial performance to enhance investor confidence.

Pharma Bio Services Business Overview & Revenue Model

Company Description

Pharma Bio Services (PBSV) is a company operating in the pharmaceutical and biotechnology sectors, specializing in providing a broad range of services including clinical research, regulatory affairs, and quality assurance. The company supports pharmaceutical and biotech companies in bringing their products to market by offering expertise and comprehensive solutions at various stages of drug development and regulatory compliance.

How the Company Makes Money

Pharma Bio Services generates revenue primarily through service contracts with pharmaceutical and biotechnology companies. The company's key revenue streams include fees for clinical trial management, regulatory consulting, and quality assurance services. PBSV partners with clients over the long term, often engaging in multi-year projects that involve extensive collaboration throughout the drug development lifecycle. Additionally, the company may earn income through strategic partnerships and alliances that enhance its service offerings and market reach.

Pharma Bio Services Financial Statement Overview

Summary

Pharma Bio Services faces significant challenges with declining revenue and profitability. Despite a strong balance sheet with substantial equity, the cash flow situation is concerning, with negative figures indicating difficulties in generating cash. The company needs to address its revenue and cash flow issues to improve its financial standing.

Income Statement

The company shows a substantial decline in revenue and profitability. The TTM gross profit margin is 31.06%, indicating some efficiency in controlling production costs despite a negative EBIT and EBITDA margin. The net profit margin is low at 0.32%, reflecting weak profitability. Revenue growth is negative, suggesting challenges in maintaining sales levels.

Balance Sheet

Pharma Bio Services has a strong equity position with a high equity ratio of 74.58%, reflecting financial stability and low leverage. However, the debt-to-equity ratio is 0.01, indicating a low level of leverage which reduces financial risk. The company’s high stockholders' equity is a positive factor in its financial health.

Cash Flow

The cash flow statement reveals negative free cash flow and operating cash flow, indicating liquidity concerns. The operating cash flow to net income ratio is negative, highlighting inefficiencies in converting income into cash flows. Free cash flow shows no growth, suggesting potential cash management issues.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
9.60M	9.51M	16.98M	19.40M	20.12M	21.56M
	Gross Profit
2.75M	2.52M	5.07M	4.88M	5.36M	6.67M
	EBIT
-941.48K	-1.29M	1.12M	1.17M	-3.85M	2.23M
	EBITDA
-692.40K	-574.28K	1.31M	1.23M	-3.78M	2.31M
	Net Income Common Stockholders
-498.36K	-777.62K	1.31M	1.01M	-2.09M	2.05M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
12.43M	12.75M	14.98M	14.46M	17.47M	17.14M
	Total Assets
16.08M	16.29M	19.90M	20.65M	23.92M	29.92M
	Total Debt
153.99K	194.03K	346.51K	487.36K	617.42K	2.79M
	Net Debt
-7.15M	-6.57M	-10.10M	-13.98M	-16.85M	-14.35M
	Total Liabilities
4.08M	2.58M	3.78M	4.09M	5.01M	7.20M
	Stockholders Equity
12.00B	13.72B	16.13M	16.56M	18.91M	22.72M
Cash Flow		Free Cash Flow
-1.88M	-726.44K	1.88M	573.19K	794.00K	1.47M
	Operating Cash Flow
-1.72M	-566.70K	1.89M	592.46K	804.84K	1.53M
	Investing Cash Flow
991.74M	-1.36M	-4.22M	-19.27K	1.30M	-28.96K
	Financing Cash Flow
-1.73M	-1.73M	-1.76M	-3.53M	-1.75M	193.68K

Pharma Bio Services Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.43
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBSV, the sentiment is Negative. The current price of 0.43 is below the 20-day moving average (MA) of 0.46, below the 50-day MA of 0.47, and below the 200-day MA of 0.49, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.89 is Neutral, neither overbought nor oversold. The STOCH value of 30.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PBSV.

Pharma Bio Services Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.82%	16.45%	-0.47%
STRM	43 Neutral	$9.75M	―	-65.35%	―	-20.67%	―
PBSV	41 Neutral	$9.87M	―	-3.81%	―	-36.50%	-181.27%
HCTI	27 Underperform	$357.17K	―	-292.41%	―	-64.77%	43.53%
SCNX	27 Underperform	$11.69M	―	-30.97%	―	-97.79%	86.73%

Pharma Bio Services Corporate Events

Pharma Bio Services Elects New Director at Annual Meeting

On May 15, 2025, Pharma-Bio Serv, Inc. held its 2025 Annual Meeting of Stockholders where Howard Spindel was elected as a Class III director until the 2028 Annual Meeting. The selection of Crowe PR PSC as the Company’s independent certified public accountants for the fiscal year ending October 31, 2025, was ratified. Additionally, a non-binding advisory vote determined that the compensation of the named executive officers will be reviewed every three years.

Spark’s Take on PBSV Stock

According to Spark, TipRanks’ AI Analyst, PBSV is a Neutral.

Pharma Bio Services is experiencing significant financial challenges with declining revenue and weak cash flows despite a strong balance sheet. The technical indicators suggest a bearish trend, and the valuation is unattractive with a negative P/E ratio. The overall outlook remains cautious, with a need for improvement in financial performance to enhance investor confidence.

To see Spark’s full report on PBSV stock, click here.